Denali Therapeutics Inc.

NASDAQ:DNLI

Biotechnology

Healthcare
$18.20 +0.40%

+$0.09 today

Market cap
$2.92B
Beta
1.01
P/E (TTM)
-8.7
EPS (TTM)
-$2.72
52W Low $12.58High $24.65

Volume 1.27M

Average 1.84M

Returns on capital

Denali Therapeutics Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-50.6%

avg -14.2%

ROIC

-52.6%

avg -28.7%

ROA

-44.8%

avg -24.0%

Analysis

ROA is currently the strongest return metric at -44.8% versus its period average of -24.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Ryan J. Watts

Co-Founder, President, Chief Executive Officer & DirectorUSD 1.42M502.12M1.34%

Alexander O. Schuth

Co-Founder, Chief Financial Officer, Chief Operating Officer & SecretaryUSD 926.18K53279.00K0.18%

Chris Walsh

General Counsel————

Joe Lewcock

Chief Scientific Officer————

Cindy Dunkle

Chief People Officer————

Katie Peng

Chief Commercial Officer—55——

Dana Andersen

Chief Technical and Manufacturing Officer————

Peter Chin

Acting Chief Medical Officer & Head of Development—58——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 1, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

2

$22,857.14

Sells

7

$1.30M

Net Transaction Value

−$1.28M

Net selling

Most Active

Schuth Alexander O.

3 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Sep 4, 26

Chin Peter Scott

Direct

Sell$36.9K
Sep 2, 26

Thornberry Nancy

Direct

Sell$247.3K
Sep 2, 26

Thornberry Nancy

Direct

Sell$14.6K
Sep 1, 26

Schuth Alexander O.

Direct

Sell$64.9K
Aug 11, 26

Schuth Alexander O.

Direct

Sell$71.6K
Jan 6, 26

Watts Ryan J.

Direct

Sell$580.8K
Jan 6, 26

Schuth Alexander O.

Direct

Sell$284.1K
Dec 11, 25

BAKER BROS. ADVISORS LP

Indirect

Buy$21K
Dec 11, 25

BAKER BROS. ADVISORS LP

Indirect

Buy$1.9K

Summary

Insiders reported 2 buys worth $22,857.14 and 7 sells worth $1.30M over the last 12 months. That adds up to net selling of $1.28M. Schuth Alexander O. was the most active insider with 3 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A6 analysts
RevenueN/AN/AN/A
N/A14 analysts
Net IncomeN/AN/AN/A
N/A14 analysts
EBITN/AN/AN/A
N/A14 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Denali Therapeutics Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about DNLI's management, answered from reported figures.

Who manages DNLI?

Denali Therapeutics Inc. (DNLI) lists 8 active executives. The top listed executive is Alexander O. Schuth, Co-Founder, Chief Financial Officer, Chief Operating Officer & Secretary.

Are DNLI insiders buying or selling?

Recent insider activity shows net buying of $16.43M.